Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL

BACKGROUND: The ExoDx Prostate(IntelliScore) (EPI) test is a non-invasive risk assessment tool for detection of high-grade prostate cancer (HGPC) that informs whether to proceed with prostate biopsy. We sought to assess the impact of EPI on the decision to biopsy in a real-world clinical setting. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Tutrone, Ronald, Donovan, Michael J., Torkler, Phillipp, Tadigotla, Vasisht, McLain, Tom, Noerholm, Mikkel, Skog, Johan, McKiernan, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655505/
https://www.ncbi.nlm.nih.gov/pubmed/32382078
http://dx.doi.org/10.1038/s41391-020-0237-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655505/
https://www.ncbi.nlm.nih.gov/pubmed/32382078
http://dx.doi.org/10.1038/s41391-020-0237-z

Ejemplares similares